RNAi Therapeutics and Technology Market Size, Share & Trends Analysis Distribution By Type (Small Interfering RNA (siRNA), MicroRNA (miRNA)), By Route of Administration (Intravenous (IV), Subcutaneous), By Delivery (Lipid Nanoparticles (LNPs), Conjugates, Others), By Region, and Segment Forecasts, 2024-2031
RNAi Therapeutics and Technology Market Size is valued at USD 1.6 Bn in 2023 and is predicted to reach USD 5.28 Bn by the year 2031 at a 16.0% CAGR during the forecast period for 2024-2031.
RNA interference (RNAi) therapeutics and technology represent a cutting-edge approach to disease treatment, utilizing the cell's natural regulatory mechanism to silence specific genes implicated in various disorders. At the core of RNAi technology lie small interfering RNA (siRNA) and microRNA (miRNA) molecules, which target and neutralize disease-causing genes with remarkable precision when introduced into the body. Through this mechanism, RNAi therapeutics offer a tailored and potent means of addressing a broad spectrum of medical conditions.
The applications of RNAi therapeutics span various diseases, ranging from genetic disorders and oncological malignancies to viral infections and neurodegenerative conditions. RNAi therapies hold promise in preventing diseases at their molecular roots by selectively silencing target genes. Additionally, RNAi technology has demonstrated efficacy in addressing cardiovascular diseases, kidney ailments, respiratory disorders, and various infectious diseases, marking a transformative shift in the landscape of medical intervention.
The increasing investments in RNAi therapy development are driving the RNAi therapeutics market forward. Driven by the acknowledgement of RNAi technology's potency in precision medicine and its expansive therapeutic potential, biotech firms and pharmaceutical companies are eagerly engaged in research and development activities, injecting substantial funds into advancing RNAi-based treatments.
Competitive Landscape
Some of the Key Players in RNAi Therapeutics and Technology Market:
- Alnylam
- Novartis
- Novo Nordisk
- Regulus therapeutics
- miRagen therapeutics
- Roche
- Santaris
- Sanofi Genzyme
- AstraZeneca
- Viridian
- Mirna Therapeutics
- Arbutus Biopharma
- OliX Pharmaceuticals, Inc
- Others
Market Segmentation:
The RNAi therapeutics and technology market is segmented based on type, Delivery, route of administration and end-user. By Type, the segmentation comprises Small Interfering RNA (siRNA), MicroRNA (miRNA). As per the Route of Administration, the market includes Intravenous (IV) and Subcutaneous. According to the Delivery, the market is segmented into Lipid Nanoparticles (LNPs), Conjugates, Others.
siRNA (small interfering RNA) is Expected to Drive the RNAi Therapeutics and Technology Market
The increasing preference for siRNA (small interfering RNA) in drug development stems from its exceptional specificity in targeting disease-causing genes, potent gene silencing activity, and advancements in delivery technologies, which collectively enhance therapeutic efficacy. SiRNAs' ability to precisely silence single genes minimizes off-target effects, making them attractive for various diseases. Moreover, the rise in research collaborations and partnerships has accelerated siRNA-based therapy development, aided by successful clinical outcomes and regulatory approvals. This collaborative momentum, coupled with ongoing advancements in the field, solidifies siRNA's position as the leading segment in the RNAi market for drug development, promising novel and effective treatments for diverse medical conditions.
Regionally, North America Led the RNAi Therapeutics and Technology Market.
North America, particularly the United States, leads the RNAi therapeutics market due to its robust biotechnology sector, encompassing top-notch universities and research institutions that drive innovation in RNAi technology. Supported by favorable regulatory agencies like the FDA, the region fosters the approval and commercialization of RNAi-based therapies. High healthcare expenditure levels and well-established healthcare systems further bolster the adoption of innovative treatments. Additionally, key players and collaborative efforts among biopharmaceutical companies and academic institutions actively propel the development and commercialization of RNAi-based treatments, solidifying North America's dominance in the global RNAi therapeutics market.
RNAi Therapeutics and Technology Market Report Scope
| Report Attribute | Specifications |
| Market Size Value In 2023 | USD 1.6 Bn |
| Revenue Forecast In 2031 | USD 5.28 Bn |
| Growth Rate CAGR | CAGR of 16.0 % from 2024 to 2031 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
| Historic Year | 2019 to 2023 |
| Forecast Year | 2024-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Type, By Delivery, By Route of Administration, |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; Southeast Asia |
| Competitive Landscape | Alnylam, Novartis, Novo Nordisk, Regulus therapeutics, miRagen therapeutics, Roche, Santaris, Sanofi Genzyme, AstraZeneca, Viridian, Mirna Therapeutics, Arbutus Biopharma, OliX Pharmaceuticals, Inc, and Others |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation RNAi Therapeutics and Technology Market -
RNAi Therapeutics and Technology Market by Type -
- Small interfering RNA (siRNA)
- MicroRNA (miRNA)
RNAi Therapeutics and Technology Market by Route of Administration -
- Intravenous (IV)
- Subcutaneous
RNAi Therapeutics and Technology Market by Delivery-
- Lipid Nanoparticles (LNPs)
- Conjugates
- Others
RNAi Therapeutics and Technology Market by Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
RNAi Therapeutics and Technology Market Size is valued at USD 1.6 Bn in 2023 and is predicted to reach USD 5.28 Bn by the year 2031
RNAi Therapeutics and Technology Market is predicted to develop at an 16.0% CAGR during the forecast period for 2024-2031.
Alnylam, Novartis, Novo Nordisk, Regulus therapeutics, miRagen therapeutics, Roche, Santaris, Sanofi Genzyme, AstraZeneca, Viridian, Mirna Therapeutic